List of works by Malcolm A Smith

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.

scientific article published on 21 August 2017

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

scientific article published on 18 June 2018

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

scientific article published on 18 February 2019

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

scientific article published on 15 July 2016

ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A report by the Pediatric Preclinical Testing Consortium

scientific article published on 09 December 2020

ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's

scientific article published on 11 September 2020

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

scientific article

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

scientific article published on 14 June 2016

Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report

scientific article published on 01 January 1994

Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

scientific article published on November 2003

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

scientific article published on 24 January 2017

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

scientific article published on 18 December 2018

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML

scientific article published on 3 May 2016

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts

scientific article

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.

scientific article

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

scientific article published on 29 April 2011

Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis

scientific article published on January 2007

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

scientific article

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

scientific article published on 24 July 2020

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

scientific article

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.

scientific article published on 30 March 2011

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

scientific article

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

scientific article published on 5 August 2016

Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts

scientific article published on 17 March 2020

Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

scientific article published on 25 April 2020

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

scientific article published on 7 February 2012

Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models

scientific article published on 16 May 2019

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

scientific article

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

scientific article

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

scientific article

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia

scientific article published on 13 February 2019

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

scientific article published on 01 November 2019

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse

scientific article published on 03 March 2016

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

scientific article published on 15 March 2016

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

scientific article published on 10 August 2010

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium

scientific article published on 22 October 2020

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

scientific article published on 30 May 2016

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program

scientific article

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

scientific article published on 24 March 2020

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program

scientific article

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.

scientific article

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

scientific article published on 09 September 2013

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

scientific article published on 16 August 2011

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article published on 18 November 2014

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program

scientific article published on 16 June 2011

Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.

scientific article published on 17 September 2017

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

scientific article published on 2 November 2011

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

scientific article published on October 2009

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

scientific article published on February 2010

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

scientific article published on 24 August 2016

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program

scientific article published on June 2008

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

scientific article published on 27 September 2014

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

scientific article

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

scientific article published on 7 July 2015

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

scientific article published on 21 September 2016

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

scientific article

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

scientific article published on December 2009

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

scientific article published on December 2010

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program

scientific article

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

scientific article

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

scientific article published on January 2008

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

scientific article published on 26 October 2013

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

scientific article published on September 2009

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

scientific article published on 15 September 2011

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.

scientific article published on 27 October 2016

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

scientific article

Initial testing of aplidin by the pediatric pre-clinical testing program.

scientific article published on September 2009

Initial testing of cisplatin by the pediatric preclinical testing program

scientific article published on May 2008

Initial testing of dasatinib by the pediatric preclinical testing program

scientific article

Initial testing of lenalidomide by the pediatric preclinical testing program

scientific article published on 25 February 2011

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

scientific article

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program

scientific article

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

scientific article published on March 2008

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

scientific article

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

scientific article

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

scientific article published on 19 October 2011

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

scientific article

Initial testing of topotecan by the pediatric preclinical testing program.

scientific article

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor

scientific article published on 11 August 2015

JAK mutations in high-risk childhood acute lymphoblastic leukemia

scholarly article

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group

scientific article

Leaching and retention of dissolved metals in particulate loaded pervious concrete columns

scientific article

Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.

scientific article published on 24 April 2014

MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.

scientific article

MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma

scientific article published on 9 December 2015

Molecular characterization of the pediatric preclinical testing panel

scientific article

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

scientific article

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.

scientific article published on 28 February 2018

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

scientific article

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

scientific article published on 23 April 2019

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

scientific article published on 23 January 2020

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

scientific article published on 9 March 2016

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

scientific article

Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.

scientific article published on February 2015

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

scientific article published on 29 June 2015

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.

scientific article

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

scientific article

Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter

scientific article published on March 2014

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

scientific article published on July 2008

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

scientific article

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

scientific article

TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney

scientific article

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

scientific article

Testing of new agents in childhood cancer preclinical models: meeting summary

scientific article published on 01 December 2002

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

scientific article published on 18 November 2011

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

scientific article

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

scientific article published on 20 February 2013

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.

scientific article published on 3 July 2017

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

scientific article published on 11 December 2017

The pediatric preclinical testing program: description of models and early testing results.

scientific article published in December 2007

Toward a drug development path that targets metastatic progression in osteosarcoma.

scientific article

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project

scientific article published on 4 December 2012

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

scientific article

Paulina is supported by:

About Paulina

Help